Reference is made to the Company’s press releases dated December 30, 2024 and January 9, 2025 relating, among other things, to the Company’s current Trademark Licensing Agreement with Tong Ren Tang Holdings, which permits the Group to use the trade name “Tong Ren Tang” and certain trademarks upon payment of license fees (with Tong Ren Tang Chinese Medicine and its subsidiaries/affiliates, and the Chinese Medicine Group and its subsidiaries/affiliates, exempt from payment of license fees) for a period from 1 January 2026 to 31 December 2027.
On November 28, 2025, Tong Ren Tang Chinese Medicine announced that it has entered into a new master trademark license agreement with Tong Ren Tang Holdings to permit Tong Ren Tang Chinese Medicine to use the trade name “Tong Ren Tang” and certain trademarks upon payment of licensing fees, resulting in changes to certain provisions of the existing Trademark License Agreement between the Company and Tong Ren Tang Holdings. On the same date, Tong Ren Tang Chinese Medicine announced that it has entered into a new master trademark licensing agreement with Tong Ren Tang Holdings to allow Tong Ren Tang Chinese Medicine to use the trade name “Tong Ren Tang” and certain patents, subject to the payment of licensing fees.
Accordingly, the Company and Tong Ren Tang Holdings have entered into the Supplemental Trademark License Agreement to review the scope of the Company’s Relevant Subsidiaries for which Tong Ren Tang Holdings is authorized to collect license fees and certain provisions of the current Trademark License Agreement, as well as to update the original annual limits set forth for the transactions contemplated by the current Trademark License Agreement for the two years ending December 31, 2026 and 2027. On November 28, 2025, Tong Ren Tang Chinese Medicine announced that it has entered into a new master trademark licensing agreement with Tong Ren Tang Holdings to permit Tong Ren Tang Chinese Medicine to use the trade name “Tong Ren Tang” and certain trademarks upon payment of licensing fees, resulting in changes to certain provisions of the existing Trademark License Agreement between the Company and Tong Ren Tang Holdings. Accordingly, the Company and Tong Ren Tang Holdings have entered into the Supplemental Trademark License Agreement to update the scope of the Company’s relevant subsidiaries for which Tong Ren Tang Holdings is authorized to collect license fees and certain provisions relating to license fees under the current Trademark License Agreement.
In this press release, unless the context otherwise requires, the following terms have the meanings ascribed to them under the Hong Kong Listing Rules: “Board” means the board of directors of the Company; “Chinese Medicine Group” means Beijing Tong Ren Tang Chinese Medicine (Hong Kong) Group Co. Ltd. (Bei Jing Tong Ren Tang Guo Yao (Xiang Gang) Ji Tuan You “Company” means Tong Ren Tang Technologies Co. Ltd. (Bei Jing Tong Ren Tang Ke Ji Fa Zhan Gu You Xian Gong Si), whose H shares are listed on the Main Board of the Hong Kong Stock Exchange; “Board” means the Board of the Hong Kong Stock Exchange; “Council” means the company; “Board” means the directors of the Company; “Chinese Medicine Group” means Beijing Tong Ren Tang Chinese Medicine (Hong Kong).
